Free Trial

Clearside Biomedical (CLSD) Competitors

Clearside Biomedical logo
$0.87 +0.02 (+2.55%)
Closing price 04:00 PM Eastern
Extended Trading
$0.85 -0.02 (-1.80%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLSD vs. RNAC, TSVT, INZY, GLUE, PVLA, LFCR, TNGX, GOSS, CRVS, and AQST

Should you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.

Clearside Biomedical vs.

Clearside Biomedical (NASDAQ:CLSD) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.

18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 9.2% of Clearside Biomedical shares are owned by company insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Clearside Biomedical has higher earnings, but lower revenue than Cartesian Therapeutics. Clearside Biomedical is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearside Biomedical$1.66M40.20-$32.49M-$0.41-2.11
Cartesian Therapeutics$34.17M6.95-$219.71M-$52.83-0.17

In the previous week, Cartesian Therapeutics had 8 more articles in the media than Clearside Biomedical. MarketBeat recorded 13 mentions for Cartesian Therapeutics and 5 mentions for Clearside Biomedical. Cartesian Therapeutics' average media sentiment score of 0.42 beat Clearside Biomedical's score of -0.13 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clearside Biomedical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cartesian Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Clearside Biomedical received 337 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 67.26% of users gave Clearside Biomedical an outperform vote.

CompanyUnderperformOutperform
Clearside BiomedicalOutperform Votes
376
67.26%
Underperform Votes
183
32.74%
Cartesian TherapeuticsOutperform Votes
39
95.12%
Underperform Votes
2
4.88%

Clearside Biomedical has a net margin of -413.83% compared to Cartesian Therapeutics' net margin of -510.72%.

Company Net Margins Return on Equity Return on Assets
Clearside Biomedical-413.83% N/A -92.90%
Cartesian Therapeutics -510.72%N/A -6.03%

Clearside Biomedical presently has a consensus price target of $5.00, suggesting a potential upside of 477.63%. Cartesian Therapeutics has a consensus price target of $42.50, suggesting a potential upside of 364.48%. Given Clearside Biomedical's stronger consensus rating and higher possible upside, equities analysts clearly believe Clearside Biomedical is more favorable than Cartesian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearside Biomedical
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cartesian Therapeutics
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

Clearside Biomedical has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Cartesian Therapeutics beats Clearside Biomedical on 9 of the 17 factors compared between the two stocks.

Get Clearside Biomedical News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLSD vs. The Competition

MetricClearside BiomedicalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$66.89M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-1.929.0626.7119.71
Price / Sales40.20251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book-3.466.456.774.50
Net Income-$32.49M$143.98M$3.23B$248.22M
7 Day Performance0.13%2.41%1.80%0.56%
1 Month Performance8.20%4.56%11.10%13.17%
1 Year Performance-35.88%-2.67%17.11%7.30%

Clearside Biomedical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLSD
Clearside Biomedical
2.2912 of 5 stars
$0.87
+2.5%
$5.00
+477.6%
-43.3%$66.89M$1.66M-1.9230
RNAC
Cartesian Therapeutics
1.5471 of 5 stars
$10.37
+1.1%
$42.50
+309.8%
-62.3%$269.14M$34.17M-0.2064News Coverage
Analyst Revision
TSVT
2seventy bio
1.5578 of 5 stars
$5.00
flat
$4.25
-15.0%
N/A$266.15M$48.37M-2.69440Positive News
INZY
Inozyme Pharma
3.0315 of 5 stars
$3.99
+1.0%
$11.75
+194.5%
-16.0%$257.60MN/A-2.5650High Trading Volume
GLUE
Monte Rosa Therapeutics
2.1813 of 5 stars
$4.11
+3.3%
$15.50
+277.1%
-6.6%$252.81M$159.49M-2.2590Positive News
Analyst Downgrade
PVLA
Palvella Therapeutics
3.8018 of 5 stars
$22.56
+2.3%
$46.29
+105.2%
N/A$249.13M$42.81M-1.86N/AEarnings Report
Analyst Revision
LFCR
Lifecore Biomedical
1.2515 of 5 stars
$6.71
-2.6%
$8.00
+19.2%
+8.2%$248.44M$130.31M-11.98690News Coverage
Analyst Forecast
TNGX
Tango Therapeutics
1.8933 of 5 stars
$2.29
+52.7%
$12.33
+438.6%
-74.7%$248.22M$40.99M-1.9490Positive News
High Trading Volume
GOSS
Gossamer Bio
3.7553 of 5 stars
$1.09
+4.8%
$7.75
+611.0%
+71.6%$247.67M$114.70M-3.41180Earnings Report
Analyst Revision
CRVS
Corvus Pharmaceuticals
2.3916 of 5 stars
$3.62
+0.3%
$16.33
+351.2%
+66.5%$246.77MN/A-3.8930Analyst Forecast
AQST
Aquestive Therapeutics
1.2964 of 5 stars
$2.45
+2.9%
$10.67
+335.4%
-28.6%$243.35M$54.23M-5.44160Positive News
Analyst Revision
Gap Up

Related Companies and Tools


This page (NASDAQ:CLSD) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners